Daryl Gaugler - Jun 5, 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jun 5, 2023
Transactions value $
-$117,571
Form type
4
Date filed
6/7/2023, 09:22 PM
Previous filing
Jun 2, 2023
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale -$38.7K -1K -4.07% $38.74 23.6K Jun 5, 2023 Direct F1
transaction PCRX Common Stock Sale -$39.2K -1.01K -4.26% $38.99 22.6K Jun 6, 2023 Direct F2
transaction PCRX Common Stock Sale -$39.6K -1.05K -4.64% $37.87 21.5K Jun 7, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.